Brief: Oasmia Pharmaceutical Q4 Operating Loss Narrows To SEK 2.1 Mln

Vivesto AB

24/02/2022 07:22

Feb 24 (Reuters) - Oasmia Pharmaceutical AB  OASM.ST :
    * YEAR-END REPORT JANUARY 1, 2021 – DECEMBER 31, 2021
    * Q4 CONSOLIDATED NET SALES AMOUNTED TO TSEK 9,639 (131)
    * Q4 OPERATING LOSS TSEK 2,068 (-59,441)

Source text for Eikon:  ID:nMFN9FdRXq 
Further company coverage:  OASM.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))